Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Significant Increase in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) saw a large growth in short interest in August. As of August 31st, there was short interest totaling 265,115 shares, a growth of 411.7% from the August 15th total of 51,809 shares. Approximately 6.3% of the company’s stock are short sold. Based on an average trading volume of 1,250,016 shares, the days-to-cover ratio is currently 0.2 days.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Bluejay Diagnostics in a research note on Wednesday, June 24th. Wall Street Zen upgraded Bluejay Diagnostics from a “sell” rating to a “hold” rating in a report on Sunday, September 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Bluejay Diagnostics Price Performance

Bluejay Diagnostics stock traded down $0.11 during mid-day trading on Friday, hitting $0.90. 319,394 shares of the company’s stock traded hands, compared to its average volume of 3,133,148. The firm has a 50 day simple moving average of $1.06 and a two-hundred day simple moving average of $1.92. Bluejay Diagnostics has a fifty-two week low of $0.82 and a fifty-two week high of $16.68. The stock has a market cap of $4.01 million, a price-to-earnings ratio of -0.13 and a beta of 0.91.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($1.12) EPS for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88.

Insider Activity

In other news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $1.40, for a total value of $48,913.20. Following the sale, the insider directly owned 92,055 shares in the company, valued at $128,877. This trade represents a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC bought a new stake in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned about 9.15% of Bluejay Diagnostics at the end of the most recent quarter. Hedge funds and other institutional investors own 18.47% of the company’s stock.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.